{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T11:22:42Z","timestamp":1773832962580,"version":"3.50.1"},"reference-count":25,"publisher":"Japanese Society of Internal Medicine","issue":"18","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2021,9,15]]},"DOI":"10.2169\/internalmedicine.6633-20","type":"journal-article","created":{"date-parts":[[2021,3,28]],"date-time":"2021-03-28T22:06:48Z","timestamp":1616969208000},"page":"2985-2989","source":"Crossref","is-referenced-by-count":3,"title":["Successful Pregnancies in a Patient with Childhood-onset Steroid-dependent Nephrotic Syndrome during Rituximab Maintenance Therapy"],"prefix":"10.2169","volume":"60","author":[{"given":"Mizuho","family":"Nara","sequence":"first","affiliation":[{"name":"Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajime","family":"Kaga","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaya","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumito","family":"Abe","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayano","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chihiro","family":"Imaizumi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Komatsuda","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Wakui","sequence":"additional","affiliation":[{"name":"Department of Life Science, Akita University Graduate School of Engineering Science, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoto","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. D&apos;Agati VD, Kaskel FJ, Falk RJ. Focal segmental glomerulosclerosis. N Engl J Med 365: 2398-2411, 2011.","DOI":"10.1056\/NEJMra1106556"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Yamamoto R, Imai E, Maruyama S, et al. Regional variations in immunosuppressive therapy in patients with primary nephrotic syndrome: the Japan nephrotic syndrome cohort study. Clin Exp Nephrol 22: 1266-1280, 2018.","DOI":"10.1007\/s10157-018-1579-x"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Yamamoto R, Imai E, Maruyama S, et al. Incidence of remission and relapse of proteinuria, end-stage kidney disease, mortality, and major outcomes in primary nephrotic syndrome: the Japan Nephrotic Syndrome Cohort Study (JSNCS). Clin Exp Nephrol 24: 526-540, 2020.","DOI":"10.1007\/s10157-020-01864-1"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Rosenberg AZ, Kopp JB. Focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 12: 502-517, 2017.","DOI":"10.2215\/CJN.05960616"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Aizawa-Yashiro T, Tsuruga K, Watanabe S, Oki E, Ito E, Tanaka H. Novel multidrug therapy for children with cyclosporine-resistant or -intolerant nephrotic syndrome. Pediatr Nephrol 26: 1255-1261, 2011.","DOI":"10.1007\/s00467-011-1876-z"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Kronbichler A, Kerschbaum J, Fernandez-Fresnedo G, et al. Rituximab treatment for relapsing minimal change disease and focal segmental glomerulosclerosis: a systematic review. Am J Nephrol 39: 322-330, 2014.","DOI":"10.1159\/000360908"},{"key":"7","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S0140-6736(14)60541-9","volume":"384","author":"K Iijima","year":"2014","unstructured":"7. Iijima K, Sako M, Nozu K, et al. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomized, placebo-controlled trial. Lancet 384: 1273-1281, 2014.","journal-title":"The Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0140-6736","issn-type":"print"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Iijima K, Sako M, Nozu K. Rituximab treatment for nephrotic syndrome in children. Curr Pediatr Rep 3: 71-77, 2015.","DOI":"10.1007\/s40124-014-0065-5"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. D&apos;Agati VD, Fogo AB, Bruijn JA, Jennette JC. Pathologic classification of focal segmental glomerulosclerosis: a working proposal. Am J Kidney Dis 43: 368-382, 2004.","DOI":"10.1053\/j.ajkd.2003.10.024"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Iwabuchi Y, Takei T, Moriyama T, Itabashi M, Nitta K. Long-term prognosis of adult patients with steroid-dependent minimal change nephrotic syndrome following rituximab treatment. Medicine (Baltimore) 93: e300, 2014.","DOI":"10.1097\/MD.0000000000000300"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11. Chakravarty EF, Murray ER, Kelman A, Farmer P. Pregnancy outcomes after maternal exposure to rituximab. Blood 117: 1499-1506, 2011.","DOI":"10.1182\/blood-2010-07-295444"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Al-Rabadi L, Ayalon R, Bonegio R, et al. Pregnancy in a patient with primary membranous nephropathy and circulating snit-PLA<sub>2<\/sub>R antibodies: a case report. Am J Kidney Dis 67: 775-778, 2016.","DOI":"10.1053\/j.ajkd.2015.10.031"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Marshall MJE, Stopforth RJ, Cragg MS. Therapeutic antibodies: what have we learn from targeting CD20 and where are we going? Front Immunol 8: 1245, 2017.","DOI":"10.3389\/fimmu.2017.01245"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Whittam DH, Tallantyre EC, Jolles S, et al. Rituximab in neurological disease: principles, evidence and practice. Pract Neurol 19: 5-20, 2019.","DOI":"10.1136\/practneurol-2018-001899"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Smith JB, Hellwig K, Fink K, et al. Rituximab, MS, and pregnancy. Neurol Neuroimmunol Neuroinflamm 7: e734, 2020.","DOI":"10.1212\/NXI.0000000000000734"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. Arthritis Rheumatol 72: 529-556, 2020.","DOI":"10.1002\/art.41191"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Krysko KM, LaHue SC, Anderson A, et al. Minimal breast milk transfer of rituximab, a monoclonal antibody used in neurological conditions. Neurol Neuroimmunol Neuroinflamm 7: e637, 2020.","DOI":"10.1212\/NXI.0000000000000637"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Kimby E, Sverrisdottir A, Elinder G. Safety of rituximab therapy during the first trimester of pregnancy: a case history. Eur J Haemotol 72: 292-295, 2004.","DOI":"10.1111\/j.1600-0609.2004.00214.x"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Ojeda-Uribe M, Gilliot C, Jung G, Drenou B, Brunot A. Administration of rituximab during the first trimester of pregnancy without consequences for the newborn. J Perinatol 26: 252-255, 2006.","DOI":"10.1038\/sj.jp.7211481"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Ponte P, Lopes MJP. Apparent safe use of single dose rituximab for recalcitrant atopic dermatitis in the first trimester of a twin pregnancy. J Am Acad Dermatol 63: 355-356, 2010.","DOI":"10.1016\/j.jaad.2009.05.015"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Perez CA, Amin J, Aguina LM, Cioffi-Lavina M, Santos ES. Primary mediastinal large B-cell lymphoma during pregnancy. Case Rep Hematol 2012: 197347, 2012.","DOI":"10.1155\/2012\/197347"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Ojeda-Uribe M, Afif N, Dahan E, et al. Exposure to abatacept or rituximab in the first trimester of pregnancy in three women with autoimmune diseases. Clin Rheumatol 32: 695-700, 2013.","DOI":"10.1007\/s10067-012-2156-4"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Sprenger-M\u00e4hr H, Zitt E, Soleiman A, Lhotta K. Successful pregnancy in a patient with pulmonary renal syndrome double-positive for anti-GBM antibodies and p-ANCA. Clin Nephrol 91: 101-106, 2019.","DOI":"10.5414\/CN109584"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Sica A, Vitiello P, Papa A, et al. Use of rituximab in NHL malt type pregnant in I\u00b0 trimester for two times. Open Med 14: 757-760, 2019.","DOI":"10.1515\/med-2019-0087"},{"key":"25","doi-asserted-by":"publisher","unstructured":"25. Hattori D, Yahagi Y, Uryu H, et al. Successful treatment with preceding low-intensity chemotherapy in a primary mediastinal large B cell lymphoma patient diagnosed at 11 weeks of pregnancy. Rinsho Ketsueki 60: 112-117, 2019 (in Japanese, Abstract in English).","DOI":"10.11406\/rinketsu.60.112"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/18\/60_6633-20\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,18]],"date-time":"2021-09-18T03:17:06Z","timestamp":1631935026000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/18\/60_6633-20\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,15]]},"references-count":25,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.6633-20","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,15]]},"article-number":"6633-20"}}